Table 4 Relative risks of the biomarkers influencing disease progression*.
| Variables (upper tertile compared with the two lower tertiles) | Relative risk (95% confidence intervals) | p Value | |
|---|---|---|---|
| sMMP‐1 >7.20 ng/ml | 0.977 (0.718 to 1.328) | 0.8817 | |
| sMMP‐3 >27.4 ng/ml | 1.174 (0.846 to 1.629) | 0.3377 | |
| sCOMP >11.4 U/l | 0.826 ( 0.613 to 1.112) | 0.2078 | |
| sP1NP >46.4 ng/ml | 1.255 (0.922 to 1.709) | 0.1493 | |
| sPIIINP >4.56 ng/ml | 1.097 (0.814 to 1.480) | 0.5425 | |
| sHA >137 mg/ml | 1.747 (1.297 to 2.353) | <0.0002 | |
| sCRP >2.7 mg/ml | 0.782 (0.568 to 1.076) | 0.1313 | |
| sYKL‐40 >88 mg/l | 0.950 (0.694 to 1.302) | 0.7504 | |
| uCTX‐I >198 µg/mmol crea | 1.360 (1.000 to 1.850) | 0.0500 | |
| uCTX‐II >346 ng/mmol crea | 2.058 (1.529 to 2.770) | <0.0001 |
*Disease progression was defined as joint space decrease ⩾0.5 mm or requirement for total hip arthroplasty at 3 years (univariate analysis after adjustment for age, sex, BMI, and treatment).